Boston, MA, July 13, 2014 --(PR.com
)-- Mark Bunnage, Vice President, Head of Chemistry Biotherapeutics Research at Pfizer will give a keynote presentation to give some perspectives on kinase drug discovery past, present, and future at the 3rd Protein Kinases & Drug Design Conference (October 23-24, 2014 in Boston, MA) by GTCbio.
Kinases, key drivers of malignant transformation and major contributors to a variety of other human pathologies, have emerged as some of the most exciting targets in drug discovery. However, with initial well-documented success stories came realization that many hurdles lie in the path of successful development of new drugs, targeting kinase signaling.
GTCbio’s 3rd Protein Kinases & Drug Design Conference, to be held in October 23-24, 2014, Boston, MA, will bring together speakers representing world-leading academic centers and pharmaceutical companies to discuss how to overcome the many hurdles and answer exciting key questions. Experts will also share their positive and negative experiences on how predictive preclinical models are with clinical efficacy and toxicology.
Sessions for 2014 Agenda:
I. Advancements in Target Identification & Validation
II. New Directions for Kinase Inhibitor Drug Discovery
III. Kinase Drug Design & Medicinal Chemistry
- Reversible vs. Irreversible Kinase Inhibitors
- Allosteric Inhibitors
IV. Selective vs. Non-selective Targeting of Protein
V. Mechanisms of Resistance to Kinase Inhibitors
VI. Lessons from Preclinical Model & Clinical Development
This conference is part of our Protein Discovery Summit 2014, which consists of this and three additional parallel conferences shown below:
Antibody & Protein Therapeutics
Protein Expression, Purification & Characterization
Protein Kinases & Drug Design
For more information, please visit www.gtcbio.com